10-Q quarterly report · filed Nov 12, 2026

Taysha Gene Therapies, Inc. (TSHA) Q3 2026 10-Q Quarterly Report

Short answer

Taysha Gene Therapies, Inc. (TSHA) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$39M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$39M
−19.5% YoY · +16.1% QoQ
EPS (diluted)
−$0.10
−11.1% YoY · +16.7% QoQ

Source: XBRL data from the Taysha Gene Therapies, Inc. (TSHA) Q3 2026 10-Q on SEC EDGAR. USD.

Taysha Gene Therapies, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue not disclosed; no product sales, nine-month revenue $0 vs $4.3M YoY
  • Operating margin not meaningful; operating loss $41.9M vs $34.0M YoY
  • R&D expense $28.8M vs $25.7M, driven by REVEAL and ASPIRE trials
  • Cash $422.8M at September 30, 2026; operating cash use $114.2M for nine months
  • June 2026 offering generated $215.6M net proceeds; cash runway into second half of 2028

Risk Factors

  • No material changes to risk factors disclosed since the December 31, 2025 Form 10-K
  • Carried-forward financial risk: adverse events could affect financial condition and results of operations
  • Carried-forward market risk: adverse events could reduce the trading price of securities

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Taysha Gene Therapies, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.